EGFR

(redirected from HER1)
Also found in: Acronyms.

EGFR

Farlex Partner Medical Dictionary © Farlex 2012

EGFR

A gene on chromosome 7p12 that encodes epidermal growth factor, a transmembrane glycoprotein of the protein kinase superfamily, which is a receptor for members of the epidermal growth factor family. Binding of the protein to a ligand induces receptor dimerisation and tyrosine autophosphorylation and leads to cell proliferation.

Molecular pathology
EGFR mutations are associated with lung cancer.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

EGFR

Abbreviation for epidermal growth factor receptor.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012

eGFR

estimated glomerular filtration rate.
Medical Dictionary, © 2009 Farlex and Partners
References in periodicals archive ?
The monoclonal antibody pertuzumab (Perjeta, Hoffmann-La Roche, Basel, Switzerland) binds to the extracellular domain of HER2 and prevents the ligand-mediated dimerization of HER2 with HER1 and HER3 by steric hindrance [37] (Figure 1).
Erlotinib and Gefitinib are selective inhibitors of HER1, whereas Lapatinib can inhibit both HER1 and HER2.
HER2 has no known direct activating ligand and may be in an activated state constitutively or become active upon heterodimerization with other family members such as HER1 and HER3.
Thankfully, Barbara, 63, is now in her1 fifth year of remission.
Negative for estrogen, progesterone and HER1 receptors
(San Jose, CA), discloses an improved method of treating lung, brain, pancreatic, breast and colon cancers that are driven by a mutation known as HER1 overexpression (also called EGFR or c-ErbB-1).
Presentation of scientific data on the HER1 and HER3 total protein assays, the HER1:HER1 homodimer assay, the HER1:HER2 and HER2:HER3 heterodimer assays and the PI3K assay (at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Geneva, Switzerland in October 2008, at the AACR Targeting the PI3-Kinase Pathway in Cancer meeting in Cambridge, MA in November 2008, and at the San Antonio Breast Cancer Symposium in December, 2008).
Erlotinib targets the human epidermal growth factor receptor (HER1) pathway, a factor "critical to cell growth" in NSCLCs as well as pancreatic cancers, according to its manufacturer, Genentech.
LAPATINIB: This drug works in a similar way to Herceptin but it targets a protein called HER1 as well as HER2.
Erlotinib is an investigational small molecule that targets the human epidermal growth factor receptor (HER1) pathway.
A 2003 study conducted by the Higher Education Research Institute (HER1) at the University of California Los Angeles (UCLA) examined the spiritual life of college students.